Carnegie Investment Counsel’s Ginkgo Bioworks DNA Stock Holding History

Carnegie Investment Counsel’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-758	Closed	-$95K	–	515
2022 Q3	$95K	Buy	+758	New	+$90.3K	﹤0.01%	467
2022 Q2	–	Sell	-3,781	Closed	-$609K	–	479
2022 Q1	$609K	Sell	3,781 -290	-7%	-$56.4K	0.02%	324
2021 Q4	$1.35M	Buy	4,071 +797	+24%	+$379K	0.04%	247
2021 Q3	$1.52M	Buy	+3,274	New	+$1.59M	0.06%	209

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Carnegie Investment Counsel's DNA Position: Q4 2022 in Review

Carnegie Investment Counsel sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 758 shares — an estimated $95K sold.

Carnegie Investment Counsel first reported a position in DNA in Q3 2021 and held it in 4 quarters. The position peaked at $1.52M in Q3 2021. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

Carnegie Investment Counsel reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
Carnegie Investment Counsel sold 758 Ginkgo Bioworks shares in Q4 2022, an estimated $95K.
Carnegie Investment Counsel first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 4 quarters.
Carnegie Investment Counsel's Ginkgo Bioworks position peaked at $1.52M in Q3 2021.
320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Carnegie Investment Counsel's 13F filing for Q4 2022, filed 24 Jan 2023.